Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India
Loading...
Date
2022-09
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Mrs Dipika Charan of MedScience (India) Publications
Abstract
Background: Depression is common yet under-reported disorder in the real-world setting. Although antidepressants have demonstrated superiority over placebo in clinical trials, many patients elicit a suboptimal response or relapse. Moreover, real-world data in the Indian population are limited. Aim and Objective: This study aims to assess and compare the efficacy and safety of escitalopram in patients with newly diagnosed depression (NDD) versus relapse in India. Materials and Methods: This is an ongoing real-world observational study of escitalopram in patients with NDD or relapse in India. Primary endpoint was change in mean Hamilton Depression Rating Scale (HAM-D 17) scores from baseline to week 8. Secondary endpoints included assessment of response/remission rates, Clinical Global Impression (CGI) scores, quality of life, suicidal tendency, and safety. Results: Data for the first 50 patients demonstrated a significant reduction in HAM-D 17 scores at week 8 (P < 0.001); patients with NDD (n = 38) elicited significantly higher improvement compared with relapsed patients (n = 12) (P < 0.001). Although patients with NDD had significantly poorer CGI (P < 0.001) and quality of life (anxiety/depression subscale) (P < 0.05) scores at baseline, an improvement was observed in both scales with no significant difference between the groups at week 8. Suicidal tendency reduced from 83.3% to 0%. No new safety concerns were observed in the study. Conclusion: Escitalopram demonstrated efficacy and was well tolerated in both, NDD and relapsed patients in the real-world setting in India, with better results achieved by NDD patients. However, more studies are required to confirm the difference across the groups.
Description
Keywords
Depression, India, Major Depressive Disorder, Observational Study, Real World, Relapse
Citation
Dharadhar S, Sharma A, Karia S. . Real-world observational study of escitalopram for newly diagnosed versus relapsed patients with major depressive disorder in India. National Journal of Physiology, Pharmacy and Pharmacology. 2022 Sept; 12(9): 1399-1407